Catalyst Event

Cogent Biosciences Inc (COGT) · Other

From KEDI U.S. Next Tech TOP10 Index (KUNTT10)

5/30/2026, 12:00:00 AM

OtherSentiment: Positive

Announced detailed positive clinical data from the PEAK Phase 3 trial of bezuclastinib for GIST at the ASCO annual meeting on May 30, 2026; median PFS was 16.5 months vs 9.2 months. High importance estimated due to significant clinical data for lead candidate.

Korean Translation

2026년 5월 30일 ASCO 연례회의에서 위장관 기질 종양(GIST) 환자 대상 베주클라스티닙 3상 PEAK 임상시험 상세 데이터를 발표함. 주요 후보물질의 유의미한 임상 데이터로 높은 중요도가 예상됨.

Related Recent Events

View Full Timeline